ストックスクリーナーアプリを入手
42.94
2.67%
-1.18
Ionis Pharmaceuticals Inc (IONS) 最新ニュース
Ionis Pharmaceuticals, Inc. (IONS) Stock Price, News, Quote & History - Yahoo! Finance Canada
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido - Zacks Investment Research
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal - Zacks Investment Research
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Liquidia Corporation (LQDA) Stock Price & News - Syfe
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. - The Motley Fool
Ionis Pharmaceuticals (NasdaqGS:IONS) Stock Forecast & Analyst Predictions - Simply Wall Street
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs - Zacks Investment Research
A kidney disease can progress to kidney failure in up to half of patients within 20 years. Ionis' drug met its trial goal. - Stock Titan
A rare genetic disease drug trial met its main goal. Otsuka plans FDA talks. - Stock Titan
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - The Motley Fool
IONS Stock Heads Toward Biggest Single-Day Slump In Over 5 Years – Retail Calls It ‘Opportunity Of A Lifetime’ - Stocktwits
Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax Bio - Barchart.com
Ionis Has Its First Neurology Launch, But Can Zanvastro Justify Its $285,000 Price? - Yahoo Finance
Precision Trading with Ionis Pharmaceuticals Inc. (IONS) Risk Zones - Stock Traders Daily
Rx Rundown: GSK, Novartis, Ionis Pharmaceuticals and more - Medical Marketing and Media
Ethan Weiss: Two Trial Flops End the "Genetics Is Undefeated" Era in Heart Drugs - finance.biggo.com
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure? - Yahoo Finance
Ionis at Wells Fargo healthcare conference: launches offset setbacks - investing.com
Ionis at Wells Fargo healthcare conference: launches offset setbacks By Investing.com - Investing.com Canada
IONS: Strategic approvals and strong launches drive growth, with pipeline poised for further milestones - TradingView
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making. - Yahoo Finance
Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue? - Zacks Investment Research
IONS Maintained by Barclays -- Price Target Lowered to $85.00 - GuruFocus
Ionis Pharmaceuticals (IONS) Institutional Ownership 2026 $IONS - MarketBeat
BofA Securities Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $91 - Moomoo
Raymond James cuts Ionis Pharmaceuticals price target on trial miss - Investing.com
Raymond James cuts Ionis Pharmaceuticals price target on trial miss By Investing.com - Investing.com Canada
Raymond James cuts Ionis Pharmaceuticals price target on trial miss By Investing.com - Investing.com India
Raymond James Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $84 - Moomoo
Retatrutide clears BLA bar while Wainua stumbles in busy July for trials - BioWorld News
IONS Maintained by Goldman Sachs -- Price Target Lowered to $56 - GuruFocus
BMO cuts Ionis Pharmaceuticals stock price target on drug failure By Investing.com - Investing.com Canada
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades - Seeking Alpha
BMO cuts Ionis Pharmaceuticals stock price target on drug failure By Investing.com - Investing.com UK
Ionis Pharmaceuticals gets $85 price target des... - Pluang
H.C. Wainwright cuts Ionis stock price target to $100 on pelacarsen removal - Investing.com
Canaccord cuts Ionis stock price target to $85 on pelacarsen trial miss - Investing.com
H.C. Wainwright cuts Ionis stock price target to $100 on pelacarsen removal - Investing.com Canada
Canaccord cuts Ionis stock price target to $85 on pelacarsen trial miss - Investing.com Canada
Needham reiterates Ionis stock rating after trial failure By Investing.com - Investing.com India
Ionis Stock Sinks 10% as Analysts Cut Targets After Pelacarsen Trial Miss - TipRanks
IONS Maintained by HC Wainwright & Co. -- Price Target Lowered to $100 - GuruFocus
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Why Is Novartis Stock Falling Today?Novartis (NYSE:NVS), Ionis Pharmaceuticals (NASDAQ:IONS), Royalty - Benzinga
Ionis Pharmaceuticals Shares Fall After Pelacarsen Phase 3 Trial Misses Primary Endpoint - Yahoo Finance
Why is Ionis Pharmaceuticals stock tumbling today? By Investing.com - Investing.com India
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander DiseaseSlideshow (NASDAQ:IONS) 2026-09-07 - Seeking Alpha
Ionis Drug Wins FDA Approval as First Alexander Disease Treatment - Yahoo
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal - Zacks Investment Research
0.25%
大文字化:
|
ボリューム (24 時間):